chlorpromazine has been researched along with Basal Ganglia Diseases in 113 studies
Chlorpromazine: The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking DOPAMINE RECEPTORS. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup.
chlorpromazine : A substituted phenothiazine in which the ring nitrogen at position 10 is attached to C-3 of an N,N-dimethylpropanamine moiety.
Basal Ganglia Diseases: Diseases of the BASAL GANGLIA including the PUTAMEN; GLOBUS PALLIDUS; claustrum; AMYGDALA; and CAUDATE NUCLEUS. DYSKINESIAS (most notably involuntary movements and alterations of the rate of movement) represent the primary clinical manifestations of these disorders. Common etiologies include CEREBROVASCULAR DISORDERS; NEURODEGENERATIVE DISEASES; and CRANIOCEREBRAL TRAUMA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The purpose of this study was to examine the efficacy and side effects of haloperidol, chlorpromazine, and lorazepam for the treatment of the symptoms of delirium in adult AIDS patients in a randomized, double-blind, comparison trial." | 9.08 | A double-blind trial of haloperidol, chlorpromazine, and lorazepam in the treatment of delirium in hospitalized AIDS patients. ( Breitbart, W; Corbera, K; Derevenco, M; Grau, C; Jacobson, P; Lund, S; Marotta, R; Platt, MM; Raymond, S; Weisman, H, 1996) |
| "A 6-week, double-blind, randomized, multicentre, parallel-group study was conducted to compare the efficacy of quetiapine ('Seroquel') (n=101) with that of chlorpromazine (n=100) in hospitalized patients with acute exacerbation of subchronic or chronic schizophrenia, or schizophreniform disorder." | 9.08 | A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia. ( Link, CG; Peuskens, J, 1997) |
| "The purpose of this study was to compare the efficacy of olanzapine with that of chlorpromazine plus benztropine in patients with treatment-resistant schizophrenia." | 9.08 | Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia. ( Bartko, JJ; Conley, RR; Gounaris, C; Hegerty, J; Lingle, J; Love, R; Peszke, M; Richardson, C; Tamminga, CA; Zaremba, S, 1998) |
| " To fully evaluate SLC6A3 as a therapeutic antipshycotic target we investigated association of the gene with responses to chlorpromazine and clozapine and with chlorpromazine-induced extrapyramidal syndrome (EPS) in the Chinese schizophrenia population." | 7.76 | Pharacogenetic effects of dopamine transporter gene polymorphisms on response to chlorpromazine and clozapine and on extrapyramidal syndrome in schizophrenia. ( Du, J; Feng, G; Gao, R; Guo, T; He, G; He, L; Li, S; Li, X; Lin, Z; Liu, J; St Clair, D; Wang, L; Wu, S; Xing, Q; Xu, M; Xu, Y; Xuan, J; Yang, Y; Yu, L; Zhang, A; Zhao, X; Zheng, Y; Zhou, J, 2010) |
| "These findings suggest that BDNF plays an important role in the susceptibility to schizophrenia and that the (GT)n repeat polymorphism of the BDNF gene may be an independent contributor to the chlorpromazine treatment-sensitive form of schizophrenia." | 7.74 | BDNF gene is a genetic risk factor for schizophrenia and is related to the chlorpromazine-induced extrapyramidal syndrome in the Chinese population. ( Feng, GY; He, G; He, L; Li, X; Lin, ZG; St Clair, D; Xu, MQ, 2008) |
| "Malignant syndrome is a disease characterized by high fever, extrapyramidal syndrome and dysautonomia recognized during or at the time of stopping administration of antipsychotic medication and it is the most severe and lethal side effect of antipsychotic medication." | 5.30 | [A case of malignant syndrome triggered by the use of haloperidol and chrorpromazine]. ( Fujimoto, K; Konishi, K; Kubota, M; Ogawa, H, 1997) |
| "The purpose of this study was to examine the efficacy and side effects of haloperidol, chlorpromazine, and lorazepam for the treatment of the symptoms of delirium in adult AIDS patients in a randomized, double-blind, comparison trial." | 5.08 | A double-blind trial of haloperidol, chlorpromazine, and lorazepam in the treatment of delirium in hospitalized AIDS patients. ( Breitbart, W; Corbera, K; Derevenco, M; Grau, C; Jacobson, P; Lund, S; Marotta, R; Platt, MM; Raymond, S; Weisman, H, 1996) |
| "A 6-week, double-blind, randomized, multicentre, parallel-group study was conducted to compare the efficacy of quetiapine ('Seroquel') (n=101) with that of chlorpromazine (n=100) in hospitalized patients with acute exacerbation of subchronic or chronic schizophrenia, or schizophreniform disorder." | 5.08 | A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia. ( Link, CG; Peuskens, J, 1997) |
| "The purpose of this study was to compare the efficacy of olanzapine with that of chlorpromazine plus benztropine in patients with treatment-resistant schizophrenia." | 5.08 | Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia. ( Bartko, JJ; Conley, RR; Gounaris, C; Hegerty, J; Lingle, J; Love, R; Peszke, M; Richardson, C; Tamminga, CA; Zaremba, S, 1998) |
| " To fully evaluate SLC6A3 as a therapeutic antipshycotic target we investigated association of the gene with responses to chlorpromazine and clozapine and with chlorpromazine-induced extrapyramidal syndrome (EPS) in the Chinese schizophrenia population." | 3.76 | Pharacogenetic effects of dopamine transporter gene polymorphisms on response to chlorpromazine and clozapine and on extrapyramidal syndrome in schizophrenia. ( Du, J; Feng, G; Gao, R; Guo, T; He, G; He, L; Li, S; Li, X; Lin, Z; Liu, J; St Clair, D; Wang, L; Wu, S; Xing, Q; Xu, M; Xu, Y; Xuan, J; Yang, Y; Yu, L; Zhang, A; Zhao, X; Zheng, Y; Zhou, J, 2010) |
| "Our study suggests that AKT1 is a susceptibility gene for schizophrenia in the Chinese population and that the AKT1 gene may play no major role in the therapeutic response to antipsychotics or in chlorpromazine-induced extrapyramidal syndrome." | 3.74 | Association of AKT1 gene polymorphisms with risk of schizophrenia and with response to antipsychotics in the Chinese population. ( Feng, GY; Gao, JJ; Guo, TW; He, G; He, L; Li, S; Xing, QH; Xu, F; Xu, MQ; Zheng, YL, 2007) |
| "These findings suggest that BDNF plays an important role in the susceptibility to schizophrenia and that the (GT)n repeat polymorphism of the BDNF gene may be an independent contributor to the chlorpromazine treatment-sensitive form of schizophrenia." | 3.74 | BDNF gene is a genetic risk factor for schizophrenia and is related to the chlorpromazine-induced extrapyramidal syndrome in the Chinese population. ( Feng, GY; He, G; He, L; Li, X; Lin, ZG; St Clair, D; Xu, MQ, 2008) |
| " It is suggested that additional studies, carefully designed, on dosage and plasma levels could help in achieving the lowest possible therapeutic dosage and thus in minimizing side effects." | 2.37 | Blood levels of neuroleptics: state of the art. ( Simpson, GM; Yadalam, K, 1985) |
| "On arrival, the Japan coma scale, pulse, respiratory rate, body temperature, and Sp(O2) were 300, 114 beats x min(-1), 26 breaths x min(-1), 39." | 1.38 | [Comatose patient with neuroleptic malignant syndrome brought by ambulance]. ( Kuroda, Y; Takinami, Y, 2012) |
| "Common adverse effect measures in psychiatric trials are typically analysed with repeated measures ANOVA, despite having distributions which violate key assumptions of that method; moreover, some adverse effects may be concentrated in vulnerable subgroups of participants." | 1.33 | More powerful two-sample tests for differences in repeated measures of adverse effects in psychiatric trials when only some patients may be at risk. ( Arndt, S; Conley, RR; McMahon, RP, 2005) |
| " While typical antipsychotics are often switched to atypical agents when adverse effects become limiting, there is little preclinical information to support this strategy, both in terms of efficacy and side effects." | 1.32 | Combined treatment of quetiapine with haloperidol in animal models of antipsychotic effect and extrapyramidal side effects: comparison with risperidone and chlorpromazine. ( Matsuoka, N; Mutoh, S; Shirakawa, K; Tada, M, 2004) |
| "Malignant syndrome is a disease characterized by high fever, extrapyramidal syndrome and dysautonomia recognized during or at the time of stopping administration of antipsychotic medication and it is the most severe and lethal side effect of antipsychotic medication." | 1.30 | [A case of malignant syndrome triggered by the use of haloperidol and chrorpromazine]. ( Fujimoto, K; Konishi, K; Kubota, M; Ogawa, H, 1997) |
| " Such variations have been attributed to individual metabolism, pharmacologic differences, and age--all of which may need careful consideration in prescribing an appropriate dosage regimen for a given patient." | 1.27 | Interpatient variations in antipsychotic therapy. ( Gershon, S; McIntyre, IM, 1985) |
| " Data were analyzed to determine the effect of anticholinergic prophylaxis, age, sex, and type and dosage of neuroleptic on the incidence of dystonic reactions." | 1.27 | Anticholinergic agents for prophylaxis of neuroleptic-induced dystonic reactions: a prospective study. ( Heiser, JF; Morrison, RL; Simpson, GM; Sramek, JJ, 1986) |
| "A historical review of the adverse reactions to neuroleptic agents--extrapyramidal side effects--is presented." | 1.27 | Extrapyramidal side effects: a historical perspective. ( Rifkin, A, 1987) |
| "Symptoms consisted of confusion, extrapyramidal symptoms, and slow-wave EEG disturbances." | 1.27 | A case of lithium-chlorpromazine interaction. ( Yassa, R, 1986) |
| " In contrast, haloperidol failed to exert a similar effect at a dosage (1." | 1.27 | Conditioned taste aversion to chlorpromazine, but not to haloperidol. ( Giardini, V, 1985) |
| "Penfluridol-treated patients experienced less drowsiness than those treated with chlorpromazine, but the severity of extrapyramidal symptoms appeared to be greater with penfluridol." | 1.26 | Penfluridol in the treatment of newly admitted schizophrenic patients in a brief therapy unit. ( Annable, L; Chouinard, G, 1976) |
| "The effect of various antipsychotic drugs on the blockade of dopaminergic receptors in striatum and limbic forebrain was examined by establishing dose-response curves for the increase in HVA and for the antagonism of d-amphetamine-induced rotation in rats with unilateral lesions of the substantia nigra." | 1.25 | On the significance of the increase in homovanillic acid (HVA) caused by antipsychotic drugs in corpus striatum and limbic forebrain. ( Dingell, JV; Hill, H; Robinson, SE; Setler, P; Stawarz, RJ; Sulser, F, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 87 (76.99) | 18.7374 |
| 1990's | 12 (10.62) | 18.2507 |
| 2000's | 10 (8.85) | 29.6817 |
| 2010's | 3 (2.65) | 24.3611 |
| 2020's | 1 (0.88) | 2.80 |
| Authors | Studies |
|---|---|
| Lange, JH | 1 |
| Reinders, JH | 1 |
| Tolboom, JT | 1 |
| Glennon, JC | 1 |
| Coolen, HK | 1 |
| Kruse, CG | 1 |
| Monteleone, P | 1 |
| Cascino, G | 1 |
| Monteleone, AM | 1 |
| Rocca, P | 1 |
| Rossi, A | 1 |
| Bertolino, A | 1 |
| Aguglia, E | 1 |
| Amore, M | 1 |
| Collantoni, E | 1 |
| Corrivetti, G | 1 |
| Cuomo, A | 1 |
| Bellomo, A | 1 |
| D'Ambrosio, E | 1 |
| Dell'Osso, L | 1 |
| Frascarelli, M | 1 |
| Giordano, GM | 1 |
| Giuliani, L | 1 |
| Marchesi, C | 1 |
| Montemagni, C | 1 |
| Oldani, L | 1 |
| Pinna, F | 1 |
| Pompili, M | 1 |
| Roncone, R | 1 |
| Rossi, R | 1 |
| Siracusano, A | 1 |
| Vita, A | 1 |
| Zeppegno, P | 1 |
| Galderisi, S | 1 |
| Maj, M | 1 |
| Xu, M | 1 |
| Xing, Q | 1 |
| Li, S | 2 |
| Zheng, Y | 1 |
| Wu, S | 1 |
| Gao, R | 1 |
| Yu, L | 1 |
| Guo, T | 1 |
| Yang, Y | 1 |
| Liu, J | 1 |
| Zhang, A | 1 |
| Zhao, X | 1 |
| He, G | 3 |
| Zhou, J | 1 |
| Wang, L | 1 |
| Xuan, J | 1 |
| Du, J | 1 |
| Li, X | 2 |
| Feng, G | 1 |
| Lin, Z | 2 |
| Xu, Y | 1 |
| St Clair, D | 2 |
| He, L | 3 |
| Barr, AM | 1 |
| Honer, WG | 1 |
| Johnson, JL | 1 |
| Wu, TK | 1 |
| Procyshyn, RM | 1 |
| Takinami, Y | 1 |
| Kuroda, Y | 1 |
| BADER, E | 1 |
| COLLIER, G | 1 |
| DEFER, B | 1 |
| LABORDE, P | 1 |
| LAUNAY, J | 1 |
| DESPAUTRE, M | 1 |
| CONRAD, K | 2 |
| DOMANOWSKY, K | 2 |
| WIESER, S | 2 |
| STECK, H | 3 |
| BOURGUIGNON, A | 3 |
| DELAY, J | 2 |
| DENIKER, P | 3 |
| LEMPERIERE, T | 2 |
| FREYHAN, FA | 1 |
| MALLER, O | 1 |
| CONSTANTINESCO, GN | 1 |
| TEMKOV, I | 1 |
| BOIADZHIEVA, M | 1 |
| HANAU, R | 1 |
| ANTONOV, L | 1 |
| Letailleur, M | 1 |
| Morin, J | 1 |
| Demay, J | 1 |
| Tada, M | 1 |
| Shirakawa, K | 1 |
| Matsuoka, N | 1 |
| Mutoh, S | 1 |
| McMahon, RP | 1 |
| Arndt, S | 1 |
| Conley, RR | 2 |
| Park, S | 1 |
| Ross-Degnan, D | 1 |
| Adams, AS | 1 |
| Sabin, J | 1 |
| Kanavos, P | 1 |
| Soumerai, SB | 1 |
| Lieberman, JA | 1 |
| Timdahl, K | 1 |
| Carlsson, A | 2 |
| Stening, G | 1 |
| Xu, MQ | 2 |
| Xing, QH | 1 |
| Zheng, YL | 1 |
| Gao, JJ | 1 |
| Guo, TW | 1 |
| Feng, GY | 2 |
| Xu, F | 1 |
| Lerner, V | 1 |
| Miodownik, C | 1 |
| Kaptsan, A | 1 |
| Bersudsky, Y | 1 |
| Libov, I | 1 |
| Sela, BA | 1 |
| Witztum, E | 1 |
| Costentin, J | 1 |
| Lin, ZG | 1 |
| Rovinskaia, SA | 1 |
| Revva, LI | 1 |
| Risch, SC | 1 |
| Groom, GP | 1 |
| Janowsky, DS | 1 |
| Tune, L | 1 |
| Coyle, JT | 1 |
| Tuason, VB | 1 |
| Escobar, JI | 1 |
| Garvey, M | 1 |
| Schiele, B | 1 |
| Cope, RV | 1 |
| Gregg, EM | 1 |
| Alfredsson, G | 1 |
| Härnryd, C | 1 |
| Wiesel, FA | 1 |
| Inoue, F | 1 |
| Janikowski, AM | 1 |
| Heikkinen, H | 1 |
| Outakoski, J | 1 |
| Meriläinen, V | 1 |
| Tuomi, A | 1 |
| Huttunen, MO | 1 |
| Breitbart, W | 1 |
| Marotta, R | 1 |
| Platt, MM | 1 |
| Weisman, H | 1 |
| Derevenco, M | 1 |
| Grau, C | 1 |
| Corbera, K | 1 |
| Raymond, S | 1 |
| Lund, S | 1 |
| Jacobson, P | 1 |
| Konishi, K | 1 |
| Fujimoto, K | 1 |
| Kubota, M | 1 |
| Ogawa, H | 1 |
| Peuskens, J | 1 |
| Link, CG | 1 |
| Dollfus, S | 1 |
| Brazo, P | 1 |
| Tamminga, CA | 1 |
| Bartko, JJ | 1 |
| Richardson, C | 1 |
| Peszke, M | 1 |
| Lingle, J | 1 |
| Hegerty, J | 1 |
| Love, R | 1 |
| Gounaris, C | 1 |
| Zaremba, S | 1 |
| Evans, JD | 1 |
| Negron, AE | 1 |
| Palmer, BW | 1 |
| Paulsen, JS | 1 |
| Heaton, RK | 1 |
| Jeste, DV | 1 |
| Gardos, G | 1 |
| Cole, JO | 3 |
| Vatsek, Ia | 1 |
| Mason, AS | 1 |
| Granacher, RP | 1 |
| Fowler, PJ | 1 |
| Zirkle, CL | 1 |
| Macko, E | 1 |
| Kaiser, C | 1 |
| Sarau, H | 1 |
| Tedeschi, DH | 1 |
| Pietzcker, A | 1 |
| Haase, HJ | 1 |
| Singh, MM | 2 |
| Kay, SR | 2 |
| Kuschinsky, K | 1 |
| Steinhart, MJ | 1 |
| Kolakowska, T | 2 |
| Wiles, DH | 2 |
| McNeilly, AS | 2 |
| Gelder, MG | 2 |
| Stawarz, RJ | 1 |
| Hill, H | 1 |
| Robinson, SE | 1 |
| Setler, P | 1 |
| Dingell, JV | 1 |
| Sulser, F | 1 |
| Sakalis, G | 1 |
| Chan, TL | 1 |
| Sathananthan, G | 1 |
| Schooler, N | 1 |
| Goldberg, S | 1 |
| Gershon, S | 3 |
| Alpert, M | 2 |
| Diamond, F | 2 |
| Weisenfreund, J | 1 |
| Taleporos, E | 1 |
| Friedhoff, AJ | 1 |
| Bourgeois, M | 1 |
| Levinson, P | 1 |
| Malen, R | 1 |
| Hogben, G | 1 |
| Smith, H | 1 |
| Beasley, BA | 1 |
| Ford, DH | 1 |
| Caroli, F | 1 |
| Littre-Poirier, MF | 1 |
| Ginestet, D | 1 |
| Hackenberg, P | 1 |
| Lange, E | 1 |
| Swett, C | 2 |
| Shapiro, S | 1 |
| Slone, D | 1 |
| Messiha, FS | 2 |
| Larson, JW | 1 |
| Chouinard, G | 3 |
| Annable, L | 2 |
| Laski, EM | 1 |
| Van Praag, HM | 1 |
| Korf, J | 1 |
| Mandelbrote, BM | 1 |
| Coleman, JH | 1 |
| Hayes, PE | 1 |
| Fontaine, R | 1 |
| Pycock, C | 1 |
| Tarsy, D | 1 |
| Marsden, CD | 1 |
| Wang, X | 1 |
| Keepers, GA | 1 |
| Casey, DE | 1 |
| Hriso, E | 1 |
| Kuhn, T | 1 |
| Masdeu, JC | 1 |
| Grundman, M | 1 |
| De Recondo, A | 1 |
| Plaisant, O | 1 |
| Lehericy, S | 1 |
| Debray, Q | 1 |
| Simpson, GM | 4 |
| Yadalam, K | 1 |
| McIntyre, IM | 1 |
| Johnson, DA | 1 |
| Hollander, H | 1 |
| Golden, J | 1 |
| Mendelson, T | 1 |
| Cortland, D | 1 |
| Krska, J | 1 |
| Sampath, G | 1 |
| Shah, A | 1 |
| Soni, SD | 1 |
| Sramek, JJ | 1 |
| Morrison, RL | 1 |
| Heiser, JF | 1 |
| Rifkin, A | 1 |
| Dufresne, RL | 1 |
| Wagner, RL | 1 |
| Yassa, R | 1 |
| Claghorn, J | 1 |
| Honigfeld, G | 1 |
| Abuzzahab, FS | 1 |
| Wang, R | 1 |
| Steinbook, R | 1 |
| Tuason, V | 1 |
| Klerman, G | 1 |
| Steinberg, S | 1 |
| Giardini, V | 1 |
| Forrest, FM | 1 |
| Van Woert, MH | 1 |
| Sethy, VH | 1 |
| Ambani, LM | 1 |
| Snyder, SH | 1 |
| Greenberg, D | 1 |
| Yamumura, HI | 1 |
| Elie, R | 1 |
| Gagnon, MA | 1 |
| Lamontagne, Y | 1 |
| Tetreault, L | 1 |
| Varga, E | 1 |
| Reiss, M | 1 |
| Cooper, TB | 1 |
| Bergner, PE | 1 |
| Lee, JH | 2 |
| Jus, A | 1 |
| Pineau, R | 1 |
| Jus, K | 1 |
| Villeneuve, A | 2 |
| Gautier, J | 1 |
| Pires, P | 1 |
| Drolet, A | 1 |
| Cote, M | 1 |
| Villeneuve, R | 1 |
| Poirier, LJ | 1 |
| Steg, G | 1 |
| Hertrich, O | 1 |
| Bullock, RJ | 1 |
| Levy, W | 1 |
| Wisniewski, K | 1 |
| Ritter, RM | 1 |
| Davidson, DE | 1 |
| Robinson, TA | 1 |
| Chien, CP | 1 |
| Haher, EJ | 1 |
| Herkert, E | 1 |
| Clark, ML | 1 |
| Huber, WK | 1 |
| Sullivan, J | 1 |
| Wood, F | 1 |
| Costiloe, JP | 1 |
| McClelland, HA | 1 |
| Blessed, G | 1 |
| Bhate, S | 1 |
| Ali, N | 1 |
| Clarke, PA | 1 |
| Shopsin, B | 1 |
| Pearson, E | 1 |
| Collins, P | 1 |
| Lindquist, NG | 1 |
| Anden, NE | 1 |
| Remr, J | 1 |
| Rubovits, R | 1 |
| Klawans, HL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicenter Ascending Dose, Double Blind, Placebo-controlled Study of NAP (AL-108) in Chronic Schizophrenia[NCT00505765] | Phase 2 | 63 participants (Actual) | Interventional | 2007-07-31 | Completed | ||
| MK-0777 for the Treatment of Cognitive Impairments in Patients With Schizophrenia[NCT00505076] | Phase 2 | 63 participants (Actual) | Interventional | 2007-07-31 | Completed | ||
| Clinical and Biomarker Assessment of Efficacy of Cognitive Remediation in Patients With Schizophrenia or Schizoaffective Disorder Stabilized on Lurasidone[NCT01173874] | Phase 3 | 120 participants (Actual) | Interventional | 2010-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The MATRICS Consensus Cognitive Battery (MCCB) measures functioning across various cognitive domains and is comprised of ten tests that assess seven cognitive domains (speed of processing, attention/vigilance, working memory, verbal learning, visual learning, reasoning and problem solving, and social cognition) Its measurements are based on timed paper-and-pencil, computerized, and orally-administered tests, as well as spatial tests using geometric cubes. MCCB composite T scores are between 40 and 60 (normal range) and < 40 (below normal range). (NCT00505765)
Timeframe: Baseline, 12 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| AL-108, 30 mg/Day | 3.9 |
| AL-108, 5 mg/Day | 4.6 |
| Placebo | 3.2 |
The MATRICS Consensus Cognitive Battery (MCCB) measures functioning across various cognitive domains and is comprised of ten tests that assess seven cognitive domains (speed of processing, attention/vigilance, working memory, verbal learning, visual learning, reasoning and problem solving, and social cognition) Its measurements are based on timed paper-and-pencil, computerized, and orally-administered tests, as well as spatial tests using geometric cubes. MCCB composite T scores are between 40 and 60 (normal range) and < 40 (below normal range). (NCT00505765)
Timeframe: Baseline, week 6
| Intervention | units on a scale (Mean) |
|---|---|
| AL-108, 30 mg/Day | 1.3 |
| AL-108, 5 mg/Day | 2.3 |
| Placebo | -0.2 |
Schizophrenia Cognition Rating Scale (SCoRS) assessed functional capacity by completing a 20-question rating scale via interviews with the subject and an informant, focusing on cognitive impairment and its impact on daily functioning. After the interview, the interviewer rated subject's overall difficulty on a Global Scale of 1-10. Higher scores indicate greater cognitive impairment. (NCT00505765)
Timeframe: Baseline, 12 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| AL-108, 30 mg/Day | -0.4 |
| AL-108, 5 mg/Day | -1.2 |
| Placebo | -0.3 |
Schizophrenia Cognition Rating Scale (SCoRS) assessed functional capacity by completing a 20-question rating scale via interviews with the subject and an informant, focusing on cognitive impairment and its impact on daily functioning. After the interview, the interviewer rated subject's overall difficulty on a Global Scale of 1-10. Higher scores indicate greater cognitive impairment. (NCT00505765)
Timeframe: Baseline, 6 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| AL-108, 30 mg/Day | 0.1 |
| AL-108, 5 mg/Day | -0.6 |
| Placebo | -0.1 |
UPSA includes 5 skill areas (subscales) with scores that each range from 0-20. The UPSA yields an overall total score which is the sum of the five subscales and ranges from 0-100. Higher scores are associated with more independent living. (NCT00505765)
Timeframe: Baseline, 12 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| AL-108, 30 mg/Day | 4.9 |
| AL-108, 5 mg/Day | 8.9 |
| Placebo | 0.3 |
UPSA includes 5 skill areas (subscales) with scores that each range from 0-20. The UPSA yields an overall total score which is the sum of the five subscales and ranges from 0-100. Higher scores are associated with more independent living. (NCT00505765)
Timeframe: Baseline, week 6
| Intervention | units on a scale (Mean) |
|---|---|
| AL-108, 30 mg/Day | 2.9 |
| AL-108, 5 mg/Day | 7.2 |
| Placebo | -0.9 |
The primary outcome measure is the composite score on the Matrics Consensus Cognitive Battery (MCCB). The MCCB composite score is a standardized mean of the seven domain scores. T-scores are standardized to normative data, and have an estimated mean of 50 and SD of 10 in the general healthy population. Data reduction for analysis of neurocognitive testing used the following steps: i) individual neurocognitive test scores at baseline and follow-up were converted to t-scores; ii) t-scores within the pre-specified cognitive domains measured by more than one test were averaged to obtain a domain-specific t-score; and iii) domain-specific t-scores were averaged to create the MCCB composite score. (NCT00505076)
Timeframe: 4 weeks
| Intervention | composite score (Mean) |
|---|---|
| MK-077 8 mg BID | 27.9 |
| MK-0777 3 mg BID | 31.3 |
| Placebo BID | 32.5 |
The Schizophrenia Cognition Rating Scale (SCoRS) assessed functional capacity. The SCoRS Interviewer Global Rating of function has a range 1 to 10. Higher ratings indicate greater impairment. (NCT00505076)
Timeframe: 4 Weeks (Baseline to End of Treatment)
| Intervention | SCoRS Score (Mean) | |
|---|---|---|
| Baseline | End of Treatment | |
| MK-077 8 mg BID | 4.1 | 4.0 |
| MK-0777 3 mg BID | 4.8 | 4.6 |
| Placebo BID | 3.8 | 3.6 |
The UCSD Performance-Based Skills Assessment assessed functional capacity. The UPSA Summary Score has a range from 0 to 120. A higher score indicates less impairment. (NCT00505076)
Timeframe: Baseline and end of treatment, a total of four weeks.
| Intervention | UPSA Summary Score (Mean) | |
|---|---|---|
| Baseline | End of Treatment | |
| MK-077 8 mg BID | 91.7 | 90.4 |
| MK-0777 3 mg BID | 85.0 | 86.3 |
| Placebo BID | 95.0 | 96.5 |
"Cognitive Assessment Interview was used to obtain information about cognitive functioning from both subject and an informant. Composite CAI scores were reported. Scale ranges from 1-7 with the following anchors:~Normal, no cognitive impairment~Borderline impairment~Mildly impaired~Moderately impaired~Markedly impaired~Severely impaired~Among the most extremely impaired" (NCT01173874)
Timeframe: 4-6 month period
| Intervention | units on a scale (Mean) |
|---|---|
| Cognitive Remediation | 2.74 |
| Cognitive Activity Control Group | 2.79 |
The UPSA-B assesses functional capacity to perform tasks similar to those in daily life. Raw scores are converted into scaled scores ranging from 0-100, with higher scores indicating better functional capacity. (NCT01173874)
Timeframe: 4-6 month period
| Intervention | units on a scale (Mean) |
|---|---|
| Cognitive Remediation | 79.74 |
| Cognitive Activity Control Group | 75.85 |
"The MATRICS Consensus Cognitive Battery (MCCB) will be used to assess cognitive function. The MCCB composite score is comprised of sub-scale measures of: a) working memory; b) attention and vigilance; c) verbal learning; d) visual learning; e) speed of processing; f) reason and problem solving; and g) social cognition. The MCCB takes 90 minutes or less to complete.~MCCB assessed 4 times: prestabilization (screening), randomization (after 6-8 weeks of lurasidone stabilization, prior to initial cognitive remediation), midpoint (after 20 cognitive remediation session), and study completion (final visit after 30 cognitive remediation sessions).~MCCB composite scores are reported as t-scores where a t-score = 50 is the population average. Every 10 points is one standard deviation. There is no range as scores are as far from population average." (NCT01173874)
Timeframe: 4-6 month period
| Intervention | units on a scale (Mean) |
|---|---|
| Cognitive Remediation | 35.39 |
| Cognitive Activity Control Group | 30.73 |
"Total PANSS score with 30 items. Each item is rated 1-7 so the minimum Total PANSS score =30 and the maximum is 210. Anchors for each item are as follows, the higher values represent an increase in severity of symptoms:~Absent~Minimal~Mild~Moderate~Moderately severe~Severe~Extremely severe" (NCT01173874)
Timeframe: 4-6 month period
| Intervention | units on a scale (Mean) |
|---|---|
| Cognitive Remediation | 58.79 |
| Cognitive Activity Control Group | 61.1 |
11 reviews available for chlorpromazine and Basal Ganglia Diseases
| Article | Year |
|---|---|
An analysis of safety and tolerability data from controlled, comparative studies of quetiapine in patients with schizophrenia, focusing on extrapyramidal symptoms.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Basal Ganglia Diseases; Chlorproma | 2007 |
Interfaces of psychopharmacology and cardiology--Part two.
Topics: Adrenergic alpha-Antagonists; Anti-Anxiety Agents; Antipsychotic Agents; Arrhythmias, Cardiac; Auton | 1981 |
Maintenance antipsychotic therapy: is the cure worse than the disease?
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Chlorpromazine; Chronic Disease; Clinical Trials as To | 1976 |
[Extrapyramidal movement disorders arising during treatment of psychoses with drugs].
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Chlorpromazine; Humans; Hyperkinesis; Movement Disorde | 1976 |
[Long-term medication in schizophrenia (author's transl)].
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Chlorpromazine; Depression; Double-Blind Method; Drug | 1978 |
Aging and the extrapyramidal system.
Topics: Aged; Aging; Basal Ganglia Diseases; Chlorpromazine; Chorea; Dopamine; Frontal Lobe; Gait; Haloperid | 1976 |
Drug induced extrapyramidal effects--a review.
Topics: Antiparkinson Agents; Basal Ganglia Diseases; Butyrophenones; Chlorpromazine; Drug Therapy, Combinat | 1975 |
Blood levels of neuroleptics: state of the art.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Chlorpromazine; Dose-Response Relationship, Drug; Drug | 1985 |
Antipsychotic medication: clinical guidelines for maintenance therapy.
Topics: Administration, Oral; Ambulatory Care; Anti-Anxiety Agents; Antipsychotic Agents; Basal Ganglia Dise | 1985 |
Nervous mechanisms involved in experimentally induced extrapyramidal disturbances.
Topics: Animals; Basal Ganglia Diseases; Benztropine; Brain; Cats; Caudate Nucleus; Cerebellar Nuclei; Chlor | 1974 |
Pathological aspects on Parkinson's syndrome.
Topics: Animals; Basal Ganglia; Basal Ganglia Diseases; Central Nervous System; Chlorpromazine; Corpus Stria | 1972 |
22 trials available for chlorpromazine and Basal Ganglia Diseases
| Article | Year |
|---|---|
Vitamin B6 treatment for tardive dyskinesia: a randomized, double-blind, placebo-controlled, crossover study.
Topics: Adult; Aged; Antipsychotic Agents; Basal Ganglia Diseases; Chlorpromazine; Cross-Over Studies; Doubl | 2007 |
Loxapine versus chlorpromazine in paranoid schizophrenia: a double-blind study.
Topics: Adult; Basal Ganglia Diseases; Chlorpromazine; Clinical Trials as Topic; Dibenzoxazepines; Dizziness | 1984 |
Effects of sulpiride and chlorpromazine on depressive symptoms in schizophrenic patients--relationship to drug concentrations.
Topics: Adolescent; Adult; Basal Ganglia Diseases; Chlorpromazine; Depression; Female; Humans; Male; Schizop | 1984 |
Molindone and weight loss.
Topics: Acute Disease; Basal Ganglia Diseases; Chlorpromazine; Double-Blind Method; Female; Humans; Male; Mo | 1993 |
A double-blind trial of haloperidol, chlorpromazine, and lorazepam in the treatment of delirium in hospitalized AIDS patients.
Topics: Adult; AIDS Dementia Complex; Basal Ganglia Diseases; Chlorpromazine; Delirium; Double-Blind Method; | 1996 |
A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Chlorpromazine; Dibenzothiazepines; Double-Blin | 1997 |
Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia.
Topics: Adult; Akathisia, Drug-Induced; Analysis of Variance; Antipsychotic Agents; Basal Ganglia Diseases; | 1998 |
Maintenance antipsychotic therapy: is the cure worse than the disease?
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Chlorpromazine; Chronic Disease; Clinical Trials as To | 1976 |
Relationships among clinical response, extrapyramidal syndrome and plasma chlorpromazine and metabolite ratios.
Topics: Adult; Basal Ganglia Diseases; Chlorpromazine; Clinical Trials as Topic; Double-Blind Method; Female | 1977 |
The neuroleptic hypothesis: study of the covariation of extrapyramidal and therapeutic drug effects.
Topics: Adolescent; Adult; Basal Ganglia Diseases; Chlorpromazine; Clinical Trials as Topic; Female; Humans; | 1978 |
[Trial of interruption of antiparkinson drugs in long term treatments with neuroleptics].
Topics: Adult; Antiparkinson Agents; Basal Ganglia Diseases; Chlorpromazine; Clinical Trials as Topic; Fluph | 1975 |
A comparative study of haloperidol and chlorpromazine in terms of clinical effects and therapeutic reversal with benztropine in schizophrenia. Theoretical implications for potency differences among neuroleptics.
Topics: Adult; Affect; Anxiety; Basal Ganglia Diseases; Benztropine; Chlorpromazine; Clinical Trials as Topi | 1975 |
The risks and benefits of clozapine versus chlorpromazine.
Topics: Adult; Basal Ganglia Diseases; Chlorpromazine; Clinical Trials as Topic; Clozapine; Dibenzazepines; | 1987 |
A controlled clinical trial of fluspirilene, a long-acting injectable neuroleptic, in schizophrenic patients with acute exacerbation.
Topics: Adult; Age Factors; Basal Ganglia Diseases; Chlorpromazine; Clinical Trials as Topic; Double-Blind M | 1986 |
Bioequivalency of generic and brand-named chlorpromazine.
Topics: Adult; Analysis of Variance; Basal Ganglia Diseases; Body Weight; Carbon Radioisotopes; Chlorpromazi | 1974 |
Penfluridol: a long-acting oral neuroleptic as therapeutic agent in chronic schizophrenia.
Topics: Adult; Analysis of Variance; Basal Ganglia Diseases; Body Weight; Chlorpromazine; Chronic Disease; C | 1974 |
Comparison of injectable haloperidol and chlorpromazine.
Topics: Acute Disease; Adult; Age Factors; Aged; Basal Ganglia Diseases; Chlorpromazine; Clinical Trials as | 1972 |
Depot phenothiazine treatment in acute psychosis: a sequential comparative clinical study.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Antiparkinson Agents; Basal Ganglia Diseases | 1973 |
A controlled comparison of metiapine and chlorpromazine in chronic schizophrenia.
Topics: Analysis of Variance; Basal Ganglia Diseases; Blood Pressure; Body Weight; Cardiovascular Diseases; | 1973 |
Evaluation of loxapine succinate in chronic schizophrenia.
Topics: Adult; Analysis of Variance; Basal Ganglia Diseases; Body Weight; Chlorpromazine; Cholesterol; Chron | 1972 |
The abrupt withdrawal of antiparkinsonian drugs in schizophrenic patients.
Topics: Adult; Aged; Antiparkinson Agents; Basal Ganglia Diseases; Behavior; Chlorpromazine; Clinical Trials | 1974 |
A controlled double-blind comparison between loxapine succinate and chlorpromazine in acute newly hospitalized schizophrenic patients.
Topics: Acute Disease; Administration, Oral; Adult; Basal Ganglia Diseases; Chlorpromazine; Clinical Trials | 1972 |
81 other studies available for chlorpromazine and Basal Ganglia Diseases
| Article | Year |
|---|---|
Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzoxazines; Biogenic Monoamines; Humans; Hyperprolac | 2007 |
Prevalence of antipsychotic-induced extrapyramidal symptoms and their association with neurocognition and social cognition in outpatients with schizophrenia in the "real-life".
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Chlorpromazine; Cognition; Female; Humans; Male | 2021 |
Pharacogenetic effects of dopamine transporter gene polymorphisms on response to chlorpromazine and clozapine and on extrapyramidal syndrome in schizophrenia.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Chlorpromazine; Clozapine; Dopamine Plasma Memb | 2010 |
A comparison of antipsychotic drug-defined daily doses versus chlorpromazine equivalent doses in patients with or without extrapyramidal motor symptoms.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Chlorpromazine; Dose-Response Relationship, Drug; Fema | 2010 |
[Comatose patient with neuroleptic malignant syndrome brought by ambulance].
Topics: Adult; Ambulances; Basal Ganglia Diseases; Chlorpromazine; Coma; Dantrolene; Drug Overdose; Female; | 2012 |
Extrapyramidal symptoms following thorazine medication.
Topics: Basal Ganglia Diseases; Chlorpromazine; Humans; Movement; Movement Disorders | 1956 |
[Clinical aspects of the syndrome of extrapyramidal behavior appearing during treatment by largactil].
Topics: Basal Ganglia Diseases; Chlorpromazine; Disease; Extrapyramidal Tracts; Humans; Syndrome | 1956 |
[Psychomotor and extraphyramidal syndromes during prolonged chlorpromazine treatment].
Topics: Basal Ganglia Diseases; Brain; Brain Diseases; Chlorpromazine; Disease; Extrapyramidal Tracts; Human | 1956 |
[Extrapyramidal seizures caused by phenothiazine treatment].
Topics: Basal Ganglia Diseases; Chlorpromazine; Disease; Extrapyramidal Tracts; Humans; Phenothiazines; Psyc | 1956 |
[Extrapyramidal seizures caused by phenothiazine treatment].
Topics: Basal Ganglia Diseases; Chlorpromazine; Disease; Extrapyramidal Tracts; Humans; Phenothiazines; Psyc | 1956 |
[Extrapyramidal seizures caused by phenothiazine treatment].
Topics: Basal Ganglia Diseases; Chlorpromazine; Disease; Extrapyramidal Tracts; Humans; Phenothiazines; Psyc | 1956 |
[Extrapyramidal seizures caused by phenothiazine treatment].
Topics: Basal Ganglia Diseases; Chlorpromazine; Disease; Extrapyramidal Tracts; Humans; Phenothiazines; Psyc | 1956 |
[Extrapyramidal syndrome in chlorpromazine and serpasil therapy; clinical symptomatology and therapeutic role].
Topics: Basal Ganglia Diseases; Chlorpromazine; Disease; Extrapyramidal Tracts; Humans; Reserpine; Schizophr | 1956 |
[Extrapyramidal syndrome in chlorpromazine and serpasil therapy; clinical symptomatology and therapeutic role].
Topics: Basal Ganglia Diseases; Chlorpromazine; Disease; Extrapyramidal Tracts; Humans; Reserpine; Schizophr | 1956 |
[Extrapyramidal syndrome in chlorpromazine and serpasil therapy; clinical symptomatology and therapeutic role].
Topics: Basal Ganglia Diseases; Chlorpromazine; Disease; Extrapyramidal Tracts; Humans; Reserpine; Schizophr | 1956 |
[Extrapyramidal syndrome in chlorpromazine and serpasil therapy; clinical symptomatology and therapeutic role].
Topics: Basal Ganglia Diseases; Chlorpromazine; Disease; Extrapyramidal Tracts; Humans; Reserpine; Schizophr | 1956 |
[Extrapyramidal movement disorders during chlorpromazine and reserpine therapy; clinical and electromyographic studies].
Topics: Basal Ganglia Diseases; Chlorpromazine; Disease; Extrapyramidal Tracts; Humans; Movement Disorders; | 1956 |
[Extrapyramidal movement disorders during chlorpromazine and reserpine therapy; clinical and electromyographic studies].
Topics: Basal Ganglia Diseases; Chlorpromazine; Disease; Extrapyramidal Tracts; Humans; Movement Disorders; | 1956 |
[Extrapyramidal movement disorders during chlorpromazine and reserpine therapy; clinical and electromyographic studies].
Topics: Basal Ganglia Diseases; Chlorpromazine; Disease; Extrapyramidal Tracts; Humans; Movement Disorders; | 1956 |
[Extrapyramidal movement disorders during chlorpromazine and reserpine therapy; clinical and electromyographic studies].
Topics: Basal Ganglia Diseases; Chlorpromazine; Disease; Extrapyramidal Tracts; Humans; Movement Disorders; | 1956 |
[Psychomotility, extrapyramidal syndrome and mode of action of neuroleptic therapies; chlorpromazine, reserpine and prochlorperazine].
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Chlorpromazine; Disease; Extrapyramidal Tracts; Humans | 1957 |
[Acute extrapyramidal accidents in the course of chlorpromazine treatment].
Topics: Accidents; Basal Ganglia Diseases; Chlorpromazine; Disease; Extrapyramidal Tracts; Humans | 1958 |
[Certain toxic manifestations during phenothiazine derivative therapy].
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Chlorpromazine; Disease; Extrapyramidal Tracts; Hepati | 1957 |
[Extrapyramidal syndromes induced by chlorpromazine and reserpine].
Topics: Basal Ganglia Diseases; Chlorpromazine; Extrapyramidal Tracts; Reserpine; Syndrome | 1960 |
[Clinical contribution to the knowledge of the extrapyramidal syndrome caused by neuroplegics].
Topics: Basal Ganglia Diseases; Brain Diseases; Chlorpromazine; Extrapyramidal Tracts; Humans; Knowledge; Mo | 1963 |
[Role of central mediators in experimental production and drug therapy of some extrapyramidal disorders].
Topics: Basal Ganglia Diseases; Central Nervous System; Chlorpromazine; Monoamine Oxidase Inhibitors; Muscle | 1961 |
[Extrapyramidal and diencephalic syndrome in the course of largactil and serpasil treatments].
Topics: Antihypertensive Agents; Basal Ganglia Diseases; Chlorpromazine; Diencephalon; Disease; Extrapyramid | 1954 |
[Extrapyramidal-like syndromes, oculogyral seizures and chlorpromazine].
Topics: Basal Ganglia Diseases; Chlorpromazine; Disease; Extrapyramidal Tracts; Eye Movements; Humans; Oculo | 1955 |
Combined treatment of quetiapine with haloperidol in animal models of antipsychotic effect and extrapyramidal side effects: comparison with risperidone and chlorpromazine.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Administration, Oral; Animals; Antipsychotic Agents; Basal G | 2004 |
More powerful two-sample tests for differences in repeated measures of adverse effects in psychiatric trials when only some patients may be at risk.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Chlorpromazine; Computer Simulation; | 2005 |
More powerful two-sample tests for differences in repeated measures of adverse effects in psychiatric trials when only some patients may be at risk.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Chlorpromazine; Computer Simulation; | 2005 |
More powerful two-sample tests for differences in repeated measures of adverse effects in psychiatric trials when only some patients may be at risk.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Chlorpromazine; Computer Simulation; | 2005 |
More powerful two-sample tests for differences in repeated measures of adverse effects in psychiatric trials when only some patients may be at risk.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Chlorpromazine; Computer Simulation; | 2005 |
More powerful two-sample tests for differences in repeated measures of adverse effects in psychiatric trials when only some patients may be at risk.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Chlorpromazine; Computer Simulation; | 2005 |
More powerful two-sample tests for differences in repeated measures of adverse effects in psychiatric trials when only some patients may be at risk.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Chlorpromazine; Computer Simulation; | 2005 |
More powerful two-sample tests for differences in repeated measures of adverse effects in psychiatric trials when only some patients may be at risk.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Chlorpromazine; Computer Simulation; | 2005 |
More powerful two-sample tests for differences in repeated measures of adverse effects in psychiatric trials when only some patients may be at risk.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Chlorpromazine; Computer Simulation; | 2005 |
More powerful two-sample tests for differences in repeated measures of adverse effects in psychiatric trials when only some patients may be at risk.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Chlorpromazine; Computer Simulation; | 2005 |
Effect of switching antipsychotics on antiparkinsonian medication use in schizophrenia: population-based study.
Topics: Adult; Age Factors; Aged; Antiparkinson Agents; Antipsychotic Agents; Basal Ganglia Diseases; Benzod | 2005 |
Comparative effectiveness of antipsychotic drugs. A commentary on: Cost Utility Of The Latest Antipsychotic Drugs In Schizophrenia Study (CUtLASS 1) and Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE).
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Chlorpromazine; Clozapine; Cost-Benefit Analysis; Huma | 2006 |
Association of AKT1 gene polymorphisms with risk of schizophrenia and with response to antipsychotics in the Chinese population.
Topics: Adult; Age of Onset; Antipsychotic Agents; Asian People; Basal Ganglia Diseases; China; Chlorpromazi | 2007 |
[Seeing a new classification of active medications in psychoses].
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Chlorpromazine; Dopamine D2 Receptor Antagonists; Huma | 2007 |
BDNF gene is a genetic risk factor for schizophrenia and is related to the chlorpromazine-induced extrapyramidal syndrome in the Chinese population.
Topics: Adult; Alleles; Antipsychotic Agents; Asian People; Basal Ganglia Diseases; Base Sequence; Brain-Der | 2008 |
[Sensory disorders arising during neuroleptic therapy].
Topics: Adolescent; Adult; Antipsychotic Agents; Basal Ganglia Diseases; Chlorpromazine; Female; Haloperidol | 1980 |
Acute extrapyramidal side effects: serum levels of neuroleptics and anticholinergics.
Topics: Acute Disease; Animals; Antipsychotic Agents; Basal Ganglia Diseases; Bipolar Disorder; Chlorpromazi | 1981 |
Neuroleptic malignant syndrome.
Topics: Adult; Basal Ganglia Diseases; Chlorpromazine; Haloperidol; Humans; Male; Syndrome | 1983 |
Neuroleptic malignant syndrome.
Topics: Basal Ganglia Diseases; Chlorpromazine; Female; Humans; Middle Aged | 1983 |
Withdrawal akinesia.
Topics: Basal Ganglia Diseases; Chlorpromazine; Humans; Male; Middle Aged; Substance Withdrawal Syndrome; Th | 1981 |
[A case of malignant syndrome triggered by the use of haloperidol and chrorpromazine].
Topics: Adult; Antipsychotic Agents; Anxiety; Autonomic Nervous System Diseases; Basal Ganglia Diseases; Chl | 1997 |
Clinical heterogeneity of schizophrenia.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Chlorpromazine; Cluster Analysis; Follow-Up Stu | 1997 |
Cognitive deficits and psychopathology in institutionalized versus community-dwelling elderly schizophrenia patients.
Topics: Aged; Antipsychotic Agents; Basal Ganglia Diseases; Chlorpromazine; Chronic Disease; Cognition Disor | 1999 |
Basic principles of rapid neuroleptization.
Topics: Antiparkinson Agents; Antipsychotic Agents; Basal Ganglia Diseases; Chlorpromazine; Fluphenazine; Ha | 1976 |
Pharmacological evaluation of clomacran, a new potent psychotropic agent.
Topics: Acridines; Adenylyl Cyclase Inhibitors; Animals; Antipsychotic Agents; Apomorphine; Autonomic Nervou | 1977 |
[Neuroleptics and the extrapyramidal system].
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Chlorpromazine; Chronic Disease; Humans; Motor Skills; | 1978 |
Dysphoric response to neuroleptic treatment in schizophrenia: its relationship to autonomic arousal and prognosis.
Topics: Adult; Antipsychotic Agents; Anxiety; Arousal; Autonomic Nervous System; Basal Ganglia Diseases; Chl | 1979 |
[Cellular effect of neuroleptics].
Topics: Adenylyl Cyclases; Basal Ganglia Diseases; Biological Transport, Active; Catecholamines; Chlorpromaz | 1975 |
Practical therapeutics. Psychotropic drugs.
Topics: Adrenergic beta-Antagonists; Antidepressive Agents; Antidepressive Agents, Tricyclic; Antiparkinson | 1975 |
Correlation between plasma levels of prolactin and chlorpromazine in psychiatric patients.
Topics: Administration, Oral; Basal Ganglia Diseases; Brief Psychiatric Rating Scale; Chlorpromazine; Female | 1975 |
On the significance of the increase in homovanillic acid (HVA) caused by antipsychotic drugs in corpus striatum and limbic forebrain.
Topics: Animals; Antipsychotic Agents; Basal Ganglia Diseases; Chlorpromazine; Clozapine; Corpus Striatum; D | 1975 |
[Tardive Dyskinesia induced by neuroleptics: a survey of 3140 patients in a psychiatric hospital].
Topics: Aged; Antiparkinson Agents; Basal Ganglia Diseases; Chlorpromazine; Diagnosis, Differential; Dyskine | 1977 |
Psychological factors in susceptibility to drug-induced extrapyramidal symptoms.
Topics: Adult; Basal Ganglia Diseases; Chlorpromazine; Dose-Response Relationship, Drug; Dyskinesia, Drug-In | 1978 |
[On the problem of irreversible brain damage due to neuroleptic long-term therapy. Experimental studies on rats (author's transl)].
Topics: Animals; Basal Ganglia Diseases; Brain Diseases; Cerebellum; Chlorpromazine; Female; Haplorhini; Mal | 1975 |
Extrapyramidal side effects in chlorpromazine recipients: emergence according to benztropine prophylaxis.
Topics: Adult; Affective Disorders, Psychotic; Basal Ganglia Diseases; Benztropine; Chlorpromazine; Drug The | 1977 |
Biochemical changes associated with drug-produced alterations in motor function and the psyche: a possible underlying mechanism.
Topics: Adult; Basal Ganglia Diseases; Cannabis; Chlorpromazine; Dopamine; Homovanillic Acid; Humans; Lyserg | 1977 |
Penfluridol in the treatment of newly admitted schizophrenic patients in a brief therapy unit.
Topics: Basal Ganglia Diseases; Chlorpromazine; Consciousness Disorders; Humans; Length of Stay; Penfluridol | 1976 |
Anticholinergic exacerbation of phenothiazine-induced extrapyramidal syndrome.
Topics: Adult; Basal Ganglia Diseases; Chlorpromazine; Humans; Substance Withdrawal Syndrome; Trifluoperazin | 1976 |
Importance of dopamine metabolism for clinical effects and side effects of neuroleptics.
Topics: Adult; Aged; Antiparkinson Agents; Basal Ganglia Diseases; Chlorpromazine; Dopamine; Dopamine Antago | 1976 |
Clinical significance of plasma chlorpromazine levels. I. Plasma levels of the drug, some of its metabolites and prolactin during acute treatment.
Topics: Acute Disease; Adult; Basal Ganglia Diseases; Chlorpromazine; Dose-Response Relationship, Drug; Fema | 1976 |
Drug-induced dystonia.
Topics: Adjustment Disorders; Adult; Basal Ganglia Diseases; Chlorpromazine; Chlorprothixene; Female; Fluphe | 1975 |
Letter: Fluphenazine with other antipsychotic drugs.
Topics: Basal Ganglia Diseases; Chlorpromazine; Drug Administration Schedule; Drug Therapy, Combination; Flu | 1975 |
Inhibition of circling behavior by neuroleptic drugs in mice with unilateral 6-hydroxydopamine lesions of the striatum.
Topics: Animals; Apomorphine; Basal Ganglia Diseases; Behavior; Biogenic Amines; Bis(4-Methyl-1-Homopiperazi | 1975 |
[Clinical studies of psychotropic drugs in pediatric patients].
Topics: Adolescent; Basal Ganglia Diseases; Child; Child, Preschool; Chlorpromazine; Diazepam; Humans; Lithi | 1992 |
Use of neuroleptic-induced extrapyramidal symptoms to predict future vulnerability to side effects.
Topics: Adult; Age Factors; Antipsychotic Agents; Basal Ganglia Diseases; Benztropine; Chlorpromazine; Disea | 1991 |
Extrapyramidal symptoms due to dopamine-blocking agents in patients with AIDS encephalopathy.
Topics: Age Factors; AIDS Dementia Complex; Antipsychotic Agents; Basal Ganglia Diseases; Chlorpromazine; Hu | 1991 |
Neurotoxicity of chlorpromazine and modulation by amantadine as a function of mouse strain.
Topics: Amantadine; Animals; Basal Ganglia Diseases; Chlorpromazine; Male; Mice; Mice, Inbred BALB C; Mice, | 1991 |
[Lenticular nucleus lesions after attempted suicide].
Topics: Adult; Basal Ganglia Diseases; Chlorpromazine; Corpus Striatum; Female; Humans; Suicide, Attempted | 1991 |
Interpatient variations in antipsychotic therapy.
Topics: Age Factors; Antipsychotic Agents; Basal Ganglia Diseases; Chlorpromazine; Dose-Response Relationshi | 1985 |
Extrapyramidal symptoms in AIDS patients given low-dose metoclopramide or chlorpromazine.
Topics: Acquired Immunodeficiency Syndrome; Basal Ganglia Diseases; Chlorpromazine; Drug Administration Sche | 1985 |
Radio receptor assay of serum neuroleptic levels in psychiatric patients.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Chlorpromazine; Dose-Response Relationship, Drug; Halo | 1986 |
Anticholinergic agents for prophylaxis of neuroleptic-induced dystonic reactions: a prospective study.
Topics: Adolescent; Adult; Antiparkinson Agents; Antipsychotic Agents; Basal Ganglia Diseases; Child; Chlorp | 1986 |
Extrapyramidal side effects: a historical perspective.
Topics: Adult; Antipsychotic Agents; Attitude to Health; Basal Ganglia Diseases; Chlorpromazine; Depressive | 1987 |
Antipsychotic-withdrawal akathisia versus antipsychotic-induced akathisia: further evidence for the existence of tardive akathisia.
Topics: Adult; Akathisia, Drug-Induced; Ambulatory Care; Antipsychotic Agents; Basal Ganglia Diseases; Chlor | 1988 |
A case of lithium-chlorpromazine interaction.
Topics: Basal Ganglia Diseases; Chlorpromazine; Confusion; Drug Interactions; Drug Therapy, Combination; Hum | 1986 |
Conditioned taste aversion to chlorpromazine, but not to haloperidol.
Topics: Animals; Avoidance Learning; Basal Ganglia Diseases; Chlorpromazine; Conditioning, Classical; Halope | 1985 |
Drug-induced extrapyramidal symptoms. A cooperative study.
Topics: Antidepressive Agents; Antipsychotic Agents; Basal Ganglia Diseases; Butyrophenones; Chlorpromazine; | 1973 |
Evolutionary origin of extrapyramidal disorders in drug-treated mental patients, its significance, and the role of neuromelanin.
Topics: Amphibians; Animals; Antipsychotic Agents; Basal Ganglia Diseases; Biological Evolution; Chlorpromaz | 1974 |
Effect of phenothiazines on central cholinergic activity.
Topics: Acetylcholine; Animals; Antipsychotic Agents; Basal Ganglia Diseases; Brain; Brain Chemistry; Chlorp | 1974 |
Antipsychotic drugs and catecholamine synapses.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Binding, Competitive; Brain; Catecholamines; Chlorprom | 1974 |
Antischizophrenic drugs: affinity for muscarinic cholinergic receptor sites in the brain predicts extrapyramidal effects.
Topics: Animals; Antipsychotic Agents; Basal Ganglia Diseases; Binding, Competitive; Brain; Chlorpromazine; | 1974 |
The extrapyramidal neuroleptic syndrome: description and measurement.
Topics: Basal Ganglia Diseases; Chlorpromazine; Electromyography; Facial Muscles; Gait; Humans; Movement Dis | 1973 |
[Neuroleptics, thymoleptics and tranquilizers in neurological therapy].
Topics: Basal Ganglia Diseases; Chlordiazepoxide; Chlorpromazine; Diazepam; Epilepsy; Extrapyramidal Tracts; | 1969 |
Efficacy of thiopropazate dihydrochloride (Dartalan) in treating persisting phenothiazine-induced choreo-athetosis and akathisia.
Topics: Aged; Antipsychotic Agents; Athetosis; Basal Ganglia Diseases; Chlorpromazine; Chorea; Female; Human | 1972 |
Chlorpromazine causing extrapyramidal dysfunction in newborn infant of psychotic mother.
Topics: Basal Ganglia Diseases; Chlorpromazine; Diphenhydramine; Female; Humans; Infant, Newborn; Infant, Ne | 1974 |
Accumulation in vitro of 35 S-chlorpromazine in the neuromelanin of human substantia nigra and locus coeruleus.
Topics: Adult; Autoradiography; Basal Ganglia Diseases; Binding Sites; Chlorpromazine; Female; Humans; Male; | 1972 |
[Neuroleptics: functional and biochemical effects].
Topics: Animals; Basal Ganglia Diseases; Blood Pressure; Brain Chemistry; Cats; Chlorpromazine; Drug Interac | 1972 |
The effect of octoclothepine on sensorimotor coordination of fine movements in chronic schizophrenics.
Topics: Adult; Basal Ganglia Diseases; Chlorpromazine; Chronic Disease; Dibenzothiepins; Female; Humans; Mid | 1972 |
The rabbit syndrome. A peculiar extrapyramidal reaction.
Topics: Aged; Anxiety; Basal Ganglia Diseases; Benztropine; Chlorpromazine; Fatigue; Female; Humans; Male; M | 1972 |
Implications of amphetamine-induced stereotyped behavior as a model for tardive dyskinesias.
Topics: Amphetamine; Animals; Basal Ganglia; Basal Ganglia Diseases; Brain Chemistry; Caudate Nucleus; Chlor | 1972 |